CN104093422B - 基于副流感病毒5的疫苗 - Google Patents

基于副流感病毒5的疫苗 Download PDF

Info

Publication number
CN104093422B
CN104093422B CN201380006495.2A CN201380006495A CN104093422B CN 104093422 B CN104093422 B CN 104093422B CN 201380006495 A CN201380006495 A CN 201380006495A CN 104093422 B CN104093422 B CN 104093422B
Authority
CN
China
Prior art keywords
piv5
virus
mice
gene
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380006495.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104093422A (zh
Inventor
何飙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia Research Foundation Inc
Original Assignee
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia Research Foundation Inc filed Critical University of Georgia Research Foundation Inc
Priority to CN201810061733.4A priority Critical patent/CN108130345A/zh
Publication of CN104093422A publication Critical patent/CN104093422A/zh
Application granted granted Critical
Publication of CN104093422B publication Critical patent/CN104093422B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18771—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380006495.2A 2012-01-24 2013-01-24 基于副流感病毒5的疫苗 Active CN104093422B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810061733.4A CN108130345A (zh) 2012-01-24 2013-01-24 基于副流感病毒5的疫苗

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261590056P 2012-01-24 2012-01-24
US201261590070P 2012-01-24 2012-01-24
US61/590070 2012-01-24
US61/590056 2012-01-24
US201261683810P 2012-08-16 2012-08-16
US61/683810 2012-08-16
PCT/US2013/022962 WO2013112720A1 (en) 2012-01-24 2013-01-24 Parainfluenza virus 5 based vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810061733.4A Division CN108130345A (zh) 2012-01-24 2013-01-24 基于副流感病毒5的疫苗

Publications (2)

Publication Number Publication Date
CN104093422A CN104093422A (zh) 2014-10-08
CN104093422B true CN104093422B (zh) 2018-02-23

Family

ID=48873896

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380006495.2A Active CN104093422B (zh) 2012-01-24 2013-01-24 基于副流感病毒5的疫苗
CN201810061733.4A Pending CN108130345A (zh) 2012-01-24 2013-01-24 基于副流感病毒5的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810061733.4A Pending CN108130345A (zh) 2012-01-24 2013-01-24 基于副流感病毒5的疫苗

Country Status (13)

Country Link
US (6) US9505807B2 (enExample)
EP (2) EP2806891B1 (enExample)
JP (3) JP6228136B2 (enExample)
CN (2) CN104093422B (enExample)
AU (1) AU2013212097B2 (enExample)
BR (1) BR112014018179B1 (enExample)
CA (2) CA2860388C (enExample)
ES (1) ES2728248T3 (enExample)
MX (1) MX359638B (enExample)
MY (1) MY173638A (enExample)
PH (1) PH12014501255B1 (enExample)
PT (1) PT2806891T (enExample)
WO (2) WO2013112690A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123276A1 (en) 2011-02-25 2012-08-30 University Of Georgia Research Foundation, Inc. Recombinant mumps virus vaccine
AU2013212097B2 (en) 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
KR101577397B1 (ko) * 2014-01-15 2015-12-28 경북대학교 산학협력단 신규한 돼지 파라인플루엔자 바이러스 5(pPIV5), 이를 포함하는 백신 조성물 및 이를 이용한 돼지 파라인플루엔자 바이러스 검정 키트
EP3288595B1 (en) * 2015-04-28 2020-12-30 The University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
US20180339038A1 (en) * 2015-06-12 2018-11-29 Mie University Human parainfluenza virus type 2 vector and vaccine
IL270876B2 (en) * 2017-05-25 2024-06-01 Univ Central Florida Res Found Inc Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
RU2681473C1 (ru) * 2018-01-16 2019-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для обнаружения генома вируса парагриппа 3 типа у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
CL2018003869A1 (es) * 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
CA3196157A1 (en) * 2020-09-21 2022-03-24 University Of Georgia Research Foundation, Inc. Piv5-based covid-19 vaccine
US20240102912A1 (en) * 2020-11-09 2024-03-28 Thrive Bioscience, Inc. Plaque counting assay method
CN113005149A (zh) * 2021-03-26 2021-06-22 中国农业大学 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
AU2022332107A1 (en) * 2021-08-26 2024-03-14 University Of Georgia Research Foundation, Inc. J paramyxovirus vaccines
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors
AU2023372210A1 (en) * 2022-11-04 2025-05-29 Blue Lake Biotechnology, Inc. Recombinant rsv vaccine: methods of making and using the same
JP2026504603A (ja) * 2023-02-06 2026-02-05 サイアンバック エルエルシー 修飾ｐｉｖ５ワクチンベクター：作製方法及び使用方法
CN116270766A (zh) * 2023-02-23 2023-06-23 天津理工大学 一种副流感病毒5型作为溶瘤病毒在抗肿瘤中的应用
CN117625560B (zh) * 2023-11-03 2025-09-16 中国农业大学 一种重组病毒rPIV5-H3及其制备方法、应用和疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046278A1 (en) * 1998-03-13 1999-09-16 Wake Forest University Viral vector directed to predetermined target cells
CN1347453A (zh) * 1999-12-10 2002-05-01 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2160038A1 (en) * 1995-07-14 1997-01-15 Biosignal Inc. Methods of screening compounds for their pharmacological relevance based on downregulation of recombinant receptors
JP2000509280A (ja) 1996-05-01 2000-07-25 アメリカ合衆国 組換えｄｎａ由来ヌクレオキャプシドタンパク質を用いるウイルストランスフェクタントの作製
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
JP2002153278A (ja) 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
AU2002327755A1 (en) 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
WO2005005645A1 (en) 2003-06-13 2005-01-20 Apath, Llc Negative strand rna virus replicon
DK2540312T3 (en) 2007-07-19 2015-07-20 Novavax Inc Chimeric avian influenza VLPs
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
FR2938840B1 (fr) 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
AU2013212097B2 (en) 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046278A1 (en) * 1998-03-13 1999-09-16 Wake Forest University Viral vector directed to predetermined target cells
CN1347453A (zh) * 1999-12-10 2002-05-01 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene;Lin Y et al.;《Journal of Virology》;20030301;第77卷(第6期);摘要，第3372页左栏第2-19行 *
Recombinant parainfluenza virus 5(PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge;Thompkins SM et al.;《Virology》;20071101;第362卷(第1期);摘要，第3页第2段 *

Also Published As

Publication number Publication date
US10752916B2 (en) 2020-08-25
WO2013112690A1 (en) 2013-08-01
PT2806891T (pt) 2019-07-01
BR112014018179B1 (pt) 2022-04-12
CA2860388A1 (en) 2013-08-01
CA2860388C (en) 2021-10-26
CN104093422A (zh) 2014-10-08
JP6228136B2 (ja) 2017-11-08
CA3128591A1 (en) 2013-08-01
US20190284578A1 (en) 2019-09-19
MX359638B (es) 2018-10-04
PH12014501255B1 (en) 2019-10-16
CN108130345A (zh) 2018-06-08
JP2020014470A (ja) 2020-01-30
US20140370050A1 (en) 2014-12-18
EP2806891A1 (en) 2014-12-03
WO2013112720A1 (en) 2013-08-01
US20170067080A1 (en) 2017-03-09
US20150086588A1 (en) 2015-03-26
MX2014008557A (es) 2014-10-24
JP2015506689A (ja) 2015-03-05
EP2806891A4 (en) 2015-08-26
EP3536341A1 (en) 2019-09-11
US9732358B2 (en) 2017-08-15
AU2013212097B2 (en) 2017-01-12
JP2018050624A (ja) 2018-04-05
PH12014501255A1 (en) 2014-09-08
BR112014018179A2 (pt) 2017-07-04
MY173638A (en) 2020-02-12
AU2013212097A1 (en) 2014-06-26
US9505807B2 (en) 2016-11-29
EP2806891B1 (en) 2019-04-10
JP6900437B2 (ja) 2021-07-07
ES2728248T3 (es) 2019-10-23
US11542527B2 (en) 2023-01-03
US20200377908A1 (en) 2020-12-03
US10329585B2 (en) 2019-06-25
US20170327845A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
US11542527B2 (en) Parainfluenza virus 5 based vaccines
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
US8475807B2 (en) Avian influenza virus live attenuated vaccine and uses thereof
BR112014006694A2 (pt) vacinas contra o vírus influenza e usos dessas
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
WO2017087492A1 (en) Influenza virus vaccine and vaccine platform
CA3123276A1 (en) Recombinant mumps virus vaccine
Le et al. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
Giles Development of a broadly reactive vaccine for highly pathogenic H5N1 influenza
US20260034205A1 (en) Modified live attenuated flu virus vaccines and uses thereof
Lai Overcoming Maternal Antibody Interference in Swine Influenza: Advancing DNA Vaccine Strateies for Enhanced Immune Protection in Piglets
WO2023196945A2 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
Baker The Packaging Signals of Influenza A and B Viruses Contribute to Their Speciation and Can Be Manipulated for Novel Vaccine Development
Baz et al. Health, Bethesda, Maryland, United States of America X 11 1Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, United States 12
Tompkins et al. Efficacy of Parainfluenza Virus 5 Mutants
Yang A novel method to produce an avian influenza vaccine bearing membrane-bound cytokines
Hashem Targeting the Highly Conserved Sequences in Influenza A Virus
WO2014101195A1 (zh) 表达小反刍兽疫病毒f蛋白的重组新城疫病毒及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant